{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:44:32Z","timestamp":1780544672365,"version":"3.54.1"},"reference-count":120,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advances in immuno\u2010oncology have provided a variety of novel therapeutics that harness the innate immune system to identify and destroy neoplastic cells. It is noteworthy that acceptable safety profiles accompany the development of these targeted therapies, which result in efficacious cancer treatment with higher survival rates and lower toxicities. Adoptive cellular therapy (ACT) has shown promising results in inducing sustainable remissions in patients suffering from refractory diseases. Two main types of ACT include engineered Chimeric Antigen Receptor (CAR) T cells and T cell receptor (TCR) T cells. The application of these immuno\u2010therapies in the last few years has been successful and has demonstrated a safe and rapid treatment regimen for solid and non\u2010solid tumors. The current review presents an insight into the clinical pharmacology aspects of immuno\u2010therapies, especially CAR\u2010T cells. Here, we summarize the current knowledge of TCR and CAR\u2010T cell immunotherapy with particular focus on the structure of CAR\u2010T cells, the effects and toxicities associated with these therapies in clinical trials, risk mitigation strategies, dose selection approaches, and cellular kinetics. Finally, the quantitative approaches and modeling techniques used in the development of CAR\u2010T cell therapies are described.<\/jats:p>","DOI":"10.1111\/cts.13349","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T06:27:04Z","timestamp":1654756024000},"page":"2057-2074","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T\u2010cellular therapy development"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-8972","authenticated-orcid":false,"given":"Johannes","family":"Kast","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Nozohouri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences School of Pharmacy, Texas Tech University Health Sciences Center  Amarillo Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9958-5579","authenticated-orcid":false,"given":"Marc R.","family":"Yago","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po\u2010Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malidi","family":"Ahamadi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-7166","authenticated-orcid":false,"given":"Vijay V.","family":"Upreti","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation, Amgen Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402244"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2803"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30823-X"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0325-1"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02128-1"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00100-z"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720692"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0164-6"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.01.005"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913146"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21941"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0203"},{"key":"e_1_2_15_21_1","volume-title":"Flow Cytometry in Drug Discovery and Development","author":"Litwin V","year":"2011"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-23"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0758"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0400-z"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0116-0"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0299-5"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2743"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211026338"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1889510"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0493"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552174"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0470"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"e_1_2_15_50_1","unstructured":"Genentech.Update on actemra\u00ae (tocilizumab) supply in the U.S 2022.https:\/\/www.gene.com\/media\/statements\/ps_081621. Accessed May 19 2022."},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1629904"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000621"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.48976"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01501-x"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2040"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12388"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003844"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2561"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01039-5"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.208"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1473368"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9606"},{"key":"e_1_2_15_74_1","unstructured":"US Food and Drug Administration.Considerations for the design of early\u2010phase clinical trials of cellular and gene therapy products \u2013 guidance for industry 2015.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/considerations\u2010design\u2010early\u2010phase\u2010clinical\u2010trials\u2010cellular\u2010and\u2010gene\u2010therapy\u2010products. Accessed May 19 2022."},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0389-8"},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803837"},{"key":"e_1_2_15_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04202-0"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4957"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2014.10.001"},{"key":"e_1_2_15_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2354"},{"key":"e_1_2_15_84_1","unstructured":"US Food and Drug Administration.FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma 2020.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010brexucabtagene\u2010autoleucel\u2010relapsed\u2010or\u2010refractory\u2010mantle\u2010cell\u2010lymphoma. Accessed May 19 2022."},{"key":"e_1_2_15_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_15_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_2_15_87_1","unstructured":"Gilead.Yescarta\u00ae receives U.S. FDA approval as first CAR T\u2010cell therapy for initial treatment of relapsed or refractory large B\u2010cell lymphoma (LBCL) 2022.https:\/\/www.gilead.com\/news\u2010and\u2010press\/press\u2010room\/press\u2010releases\/2022\/4\/yescarta\u2010receives\u2010us\u2010fda\u2010approval\u2010as\u2010first\u2010car\u2010tcell\u2010therapy\u2010for\u2010initial\u2010treatment\u2010of\u2010relapsed\u2010or\u2010refractory\u2010large\u2010bcell\u2010lymphoma\u2010lbcl. Accessed May 19 2022."},{"key":"e_1_2_15_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1295"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1659"},{"key":"e_1_2_15_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1125"},{"key":"e_1_2_15_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122941"},{"key":"e_1_2_15_92_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2019.0734"},{"key":"e_1_2_15_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12372"},{"key":"e_1_2_15_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2019.110125"},{"key":"e_1_2_15_95_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045027"},{"key":"e_1_2_15_96_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00579-9"},{"key":"e_1_2_15_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2018.08.018"},{"key":"e_1_2_15_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12636"},{"issue":"1","key":"e_1_2_15_99_1","first-page":"S147","article-title":"Chimeric antigen receptor T cell therapies: a review of cellular kinetic\u2010pharmacodynamic modeling approaches","volume":"60","author":"Chaudhury A","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_15_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1688616"},{"key":"e_1_2_15_101_1","first-page":"20210229","article-title":"The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy","volume":"288","author":"Kimmel GJ","year":"2021","journal-title":"Proc Biol Sci"},{"key":"e_1_2_15_102_1","unstructured":"US Food and Drug Administration.Project Optimus \u2013 Reforming the dose optimization and dose selection paradigm in oncology 2022.https:\/\/www.fda.gov\/about\u2010fda\/oncology\u2010center\u2010excellence\/project\u2010optimus. Accessed May 19 2022."},{"key":"e_1_2_15_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640082"},{"key":"e_1_2_15_104_1","unstructured":"Allogene Therapeutics.Allogeneic car T therapy\u2014the next revolution in cell therapy 2022.https:\/\/allogene.com\/allocar\u2010t\/. Accessed April 20 2022."},{"key":"e_1_2_15_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14475"},{"key":"e_1_2_15_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2529"},{"key":"e_1_2_15_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"e_1_2_15_108_1","unstructured":"Allogene Therapeutics.Allogene therapeutics CD19 forum 2021.https:\/\/ir.allogene.com\/static\u2010files\/7a26a1c0\u201055f9\u20104474\u2010a362\u20109a49b598c43c. Accessed July 15 2021."},{"key":"e_1_2_15_109_1","unstructured":"Allogene Therapeutics.Allogene therapeutics reports FDA clinical hold of AlloCAR T trials based on a single patient case in ALPHA2 trial 2021.https:\/\/ir.allogene.com\/news\u2010releases\/news\u2010release\u2010details\/allogene\u2010therapeutics\u2010reports\u2010fda\u2010clinical\u2010hold\u2010allocar\u2010t\u2010trials. Accessed May 19 2022."},{"key":"e_1_2_15_110_1","unstructured":"Allogene Therapeutics.Allogene therapeutics announces removal of FDA clinical hold across all AlloCAR T\u2122 clinical trials 2022.https:\/\/ir.allogene.com\/news\u2010releases\/news\u2010release\u2010details\/allogene\u2010therapeutics\u2010announces\u2010removal\u2010fda\u2010clinical\u2010hold\u2010across. Accessed May 19 2022."},{"key":"e_1_2_15_111_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_2_15_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"e_1_2_15_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140641"},{"key":"e_1_2_15_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145572"},{"key":"e_1_2_15_115_1","unstructured":"Allogene Therapeutics.Allogene therapeutics reports positive results from phase 1 UNIVERSAL study of single dose ALLO\u2010715 AlloCAR T\u2122 cell therapy in relapsed\/refractory multiple myeloma at the 63rd american society of hematology annual meeting 2021. <https:\/\/ir.allogene.com\/news\u2010releases\/news\u2010release\u2010details\/allogene\u2010therapeutics\u2010reports\u2010positive\u2010results\u2010phase\u20101\u2010universal>. Accessed May 19 2022."},{"key":"e_1_2_15_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533033819831068"},{"key":"e_1_2_15_117_1","unstructured":"Immunocore.Immunocore announces FDA approval of KIMMTRAK\u00ae (tebentafusp\u2010tebn) for the treatment of unresectable or metastatic uveal melanoma 2022. <https:\/\/ir.immunocore.com\/news\u2010releases\/news\u2010release\u2010details\/immunocore\u2010announces\u2010fda\u2010approval\u2010kimmtrakr\u2010tebentafusp\u2010tebn>. Accessed May 19 2022."},{"key":"e_1_2_15_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"e_1_2_15_119_1","unstructured":"Adaptimmune.Adaptimmune reports positive results from its pivotal SPEARHEAD\u20101 trial in patients with synovial sarcoma and MRCLS at CTOS 2021. <https:\/\/www.adaptimmune.com\/investors\u2010and\u2010media\/news\u2010center\/press\u2010releases\/detail\/202\/adaptimmune\u2010reports\u2010positive\u2010results\u2010from\u2010its\u2010pivotal>. Accessed May 19 2022."},{"key":"e_1_2_15_120_1","unstructured":"Immatics Biotechnology.Immatics presents data update on dose escalation from ongoing ACTengine\u00ae cell therapy programs \u2013 press release 2021.https:\/\/investors.immatics.com\/news\u2010releases\/news\u2010release\u2010details\/immatics\u2010presents\u2010data\u2010update\u2010dose\u2010escalation\u2010ongoing\u2010actenginer. Accessed May 19 2022."},{"key":"e_1_2_15_121_1","unstructured":"Medigene.Medigene reports preliminary efficacy and immune monitoring data of phase i of phase i\/ii mdg1011 trial in blood cancers 2022.https:\/\/www.medigene.com\/investors\u2010media\/press\u2010releases\/detail\/medigene\u2010reports\u2010preliminary\u2010efficacy\u2010and\u2010immune\u2010monitoring\u2010data\u2010of\u2010phase\u2010i\u2010of\u2010phase\u2010i\u2010ii\u2010mdg1011\u2010trial\u2010in\u2010blood\u2010cancers\u20101. Accessed May 19 2022."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13349","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T18:15:47Z","timestamp":1692728147000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":120,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/cts.13349"],"URL":"https:\/\/doi.org\/10.1111\/cts.13349","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"2022-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}